Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

HEPARIN AND HEPARAN SULPHATE: FROM SEQUENCE DETERMINATION TO THERAPEUTIC STRATEGIES FOR PARKINSON’S DISEASE

Descrizione del progetto

Nuova strumentazione per sequenziare le strutture di eparan solfato

L’eparan solfato (HS, Heparan Sulphate) è un polisaccaride presente nei tessuti animali. L’HS si lega a una varietà di legandi proteici e regola una serie di attività biologiche, tra cui lo sviluppo, l’angiogenesi, la coagulazione del sangue e la metastasi tumorale. Il progetto HS-SEQ, finanziato dall’UE, intende affrontare la mancanza di metodi per il sequenziamento delle strutture HS, sviluppando una nuova strumentazione in grado di registrare contemporaneamente numerose proprietà molecolari, quali il peso molecolare attraverso la spettroscopia di massa, le sezioni trasversali di collisione attraverso la spettroscopia per mobilità ionica e le proprietà vibrazionali attraverso la spettroscopia infrarossa ionica in fase gassosa. Le applicazioni della nuova tecnologia consentiranno l’identificazione dei codici HS che promuovono la generazione di neuroni dopaminergici derivati da cellule staminali umane pluripotenti, per la terapia cellulare sostitutiva nel morbo di Parkinson.

Obiettivo

Heparin and heparan sulphate (HS) are highly sulfated polysaccharides that reside on the cell surface and extracellular matrix of all mammalian cell types. Understanding their functions has tremendous potential to unlock the next generation of heparin-based diagnostics and therapeutics for multiple diseases including inflammatory and neurological diseases, cancer, and wound healing. Despite this promise, it is very difficult to harness this biomedical potential due to a fundamental technology bottleneck - lack of methods for the sequencing of HS structures to define the natural “HS codes” that underpin many biological functions. HS-SEQ will address this hurdle and will place Europe in the leading position in the emerging field of glycomics of heparin and HS. It is our vision that robust sequencing methods for heparin and HS will only be possible when new instrumentation will be developed that can simultaneously record multiple molecular properties such as molecular weight by mass spectrometry (MS), collisional cross sections (CCS) by ion mobility spectroscopy (IMS) and vibrational properties by gas-phase infra-red (IR) ion spectroscopy. To implement such a platform, large collections of well-defined HS saccharide standards are needed to generate reference databases that can match molecular properties to structural features. To obtain the required collection of HS saccharides, HS-SEQ will develop and implement an automated platform for chemoenzymatic synthesis of such compounds. The synthetic HS saccharides will also provide unique opportunities to develop an antibody toolkit to identify epitopes expressed by cells/tissues. Specific transformational applications of the new technology will be pursued: (i) identify HS codes that promote the generation of dopaminergic neurons from human pluripotent stem cells (hPSCs) for cell replacement therapy in Parkinson’s disease; and (ii) achieve unprecedented in-depth analysis of pharmaceutical and next-generation heparins.

Invito a presentare proposte

H2020-FETOPEN-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-FETOPEN-2018-2019-2020-01

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

UNIVERSITEIT UTRECHT
Contribution nette de l'UE
€ 864 400,00
Indirizzo
HEIDELBERGLAAN 8
3584 CS Utrecht
Paesi Bassi

Mostra sulla mappa

Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 864 400,00

Partecipanti (8)